BCEL — Atreca Share Price
0.000.00%
Last trade - 00:00- $4.06m
- -$17.32m
- 10
- 50
- 14
- 14
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.38 | ||
| Price to Tang. Book | 0.38 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -926.5% | ||
| Return on Equity | -182.7% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.
Directors
- Brian Atwood NEC (68)
- John Orwin PRE (55)
- Tito Serafini CFD (57)
- Herbert Cross CFO (49)
- Courtney Phillips GCN (46)
- Stephen Brady DRC (50)
- Stacey Ma DRC
- William Robinson DRC (53)
- Kristine Ball IND (49)
- Franklin Berger IND (71)
- David Lacey IND (69)
- Lindsey Rolfe IND (53)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- June 11th, 2010
- Public Since
- June 20th, 2019
- No. of Shareholders
- 50
- No. of Employees
- 90
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 45,153,725
- Address
- 835 Industrial Road, SAN CARLOS, 94070
- Web
- https://www.atreca.com/
- Phone
- +1 6505952595
- Auditors
- OUM & CO. LLP
Upcoming Events for BCEL
Q2 2024 Atreca Inc Earnings Release
Q3 2024 Atreca Inc Earnings Release
Similar to BCEL
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the Atreca share price?
As of Today at 19:26 UTC, shares in Atreca are trading at $0.09. This share price information is delayed by 15 minutes.
How has the Atreca share price performed this year?
Shares in Atreca last closed at $0.09 and the price had moved by -92.37% over the past 365 days. In terms of relative price strength the Atreca share price has underperformed the S&P500 Index by -93.41% over the past year.
What are the analyst and broker recommendations for Atreca?
The overall consensus recommendation for Atreca is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Atreca dividend yield?
Atreca does not currently pay a dividend.
Does Atreca pay a dividend?
Atreca does not currently pay a dividend.
When does Atreca next pay dividends?
Atreca does not currently pay a dividend.
How do I buy Atreca shares?
To buy shares in Atreca you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Atreca?
As of the previous close price of $0.09, shares in Atreca had a market capitalisation of $4.06m.
Where are Atreca shares listed?
Here are the trading details for Atreca:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: BCEL
What kind of share is Atreca?
Based on an overall assessment of its quality, value and momentum Atreca is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Atreca share price forecast for 2024?
The analyst consensus target price for shares in Atreca is $2.00. That is 2122.22% above the last closing price of $0.09.
Analysts covering Atreca currently have a consensus Earnings Per Share (EPS) forecast of -$2.04 for the next financial year.
Find out moreWhat is the trend in the Atreca share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Atreca. Over the past six months, its share price has underperformed the S&P500 Index by -69.87%.
As of the last closing price of $0.09, shares in Atreca were trading -55.12% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Atreca PE Ratio?
The Atreca PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Atreca?
Atreca's management team is headed by:
- Brian Atwood - NEC
- John Orwin - PRE
- Tito Serafini - CFD
- Herbert Cross - CFO
- Courtney Phillips - GCN
- Stephen Brady - DRC
- Stacey Ma - DRC
- William Robinson - DRC
- Kristine Ball - IND
- Franklin Berger - IND
- David Lacey - IND
- Lindsey Rolfe - IND